{"title":"[Human papillomavirus (HPV) vaccination for cancer prevention].","authors":"Julius Benedikt Schneede, Peter Schneede","doi":"10.1007/s00120-025-02597-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2005, the first approval study of a preventive quadrivalent human papillomavirus (HPV) vaccine in young women triggered vaccination strategies around the world.</p><p><strong>Objective: </strong>We aimed to investigate how successful these vaccination interventions have been in preventing cancer so far.</p><p><strong>Methods: </strong>To this end, we reviewed the relevant literature of the past two decades regarding vaccination rates and the subsequent decline in HPV-associated diseases worldwide.</p><p><strong>Results: </strong>For various reasons, many countries that offer HPV vaccinations are still missing their goals for primary cancer prevention. In Germany, for example, vaccination rates are completely inadequate, and urologists are not even recognized as vaccinators.</p><p><strong>Conclusion: </strong>Cancer prevention through HPV vaccination is zur Hausen's scientific legacy to the world. However, each country must continuously analyze and combat its specific reasons for failing in HPV vaccination. New HPV vaccines will continue the global success story in the future.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-025-02597-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In 2005, the first approval study of a preventive quadrivalent human papillomavirus (HPV) vaccine in young women triggered vaccination strategies around the world.
Objective: We aimed to investigate how successful these vaccination interventions have been in preventing cancer so far.
Methods: To this end, we reviewed the relevant literature of the past two decades regarding vaccination rates and the subsequent decline in HPV-associated diseases worldwide.
Results: For various reasons, many countries that offer HPV vaccinations are still missing their goals for primary cancer prevention. In Germany, for example, vaccination rates are completely inadequate, and urologists are not even recognized as vaccinators.
Conclusion: Cancer prevention through HPV vaccination is zur Hausen's scientific legacy to the world. However, each country must continuously analyze and combat its specific reasons for failing in HPV vaccination. New HPV vaccines will continue the global success story in the future.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
